Changes in cardiac structure in hypertension produced by placental ischemia in pregnant rats: Effect of tumor necrosis factor blockade

Journal of Hypertension

Volumn 29, Issue 6, 2011, Pages 1203-1212

  Gutkowska, Jolanta ^a   Granger, Joey P ^b   Lamarca, Babbette B ^b   Danalache, Bogdan A ^a   Wang, Donghao ^a   Jankowski, Marek ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

heart; hypertension; oxytocin; pregnancy; rat; TNF

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CD31 ANTIGEN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ETANERCEPT; OXYTOCIN RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CAPILLARY DENSITY; CONTROLLED STUDY; DISEASE MARKER; ENZYME PHOSPHORYLATION; FEMALE; GESTATIONAL AGE; HEART HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HYPERTENSION; NONHUMAN; NUCLEOTIDE SEQUENCE; PLACENTA DISORDER; PLACENTA ISCHEMIA; PREECLAMPSIA; PREGNANCY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

EID: 85027943815     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3283468392     Document Type: Article

References (53)

1. Simmons LA, Gillin AG, Jeremy RW. Structural and functional changes in left ventricle during normotensive and preeclamptic pregnancy. Am J Physiol Heart Circ Physiol 2002; 283:H1627-1633.
2. Melchiorre K, Sutherland GR, Baltabaeva A, Liberati M, Thilaganathan B. Maternal cardiac dysfunction and remodeling in women with preeclampsia at term. Hypertension 2011; 57:85-93.
3. Slangen BF, van Ingen Schenau DS, van Gorp AW, De Mey JG, Peeters LL. Aortic distensibility and compliance in conscious pregnant rats. Am J Physiol 1997; 272:H1260-1265.
4. Jankowski M, Wang D, Mukaddam-Daher S, Gutkowska J. Pregnancy alters nitric oxide synthase and natriuretic peptide systems in the rat left ventricle. J Endocrinol 2005; 184:209-217. (Pubitemid 40207575)
5. Gonzalez AM, Osorio JC, Manlhiot C, Gruber D, Homma S, Mital S. Hypertrophy signaling during peripartum cardiac remodeling. Am J Physiol Heart Circ Physiol 2007; 293:H3008-3013. (Pubitemid 350106525)
6. Mukaddam-Daher S, Jankowski M, Wang D, Menaouar A, Gutkowska J. Regulation of cardiac oxytocin system and natriuretic peptide during rat gestation and postpartum. J Endocrinol 2002; 175:211-216. (Pubitemid 35276599)
7. Granger JP, Alexander BT, Bennett WA, Khalil RA. Pathophysiology of pregnancy-induced hypertension. Am J Hypertens 2001; 14:178S-185S. (Pubitemid 32506713)
8. Jankowski M. Angiogenesis inhibition and preeclampsia. J Hypertens 2009; 27:707-708.
9. Shah DM. Role of the renin-angiotensin system in the pathogenesis of preeclampsia. Am J Physiol Renal Physiol 2005; 288:F614-625. (Pubitemid 40381727)
10. Khalil RA, Granger JP. Vascular mechanisms of increased arterial pressure in preeclampsia: lessons from animal models. Am J Physiol Regul Integr Comp Physiol 2002; 283:R29-45. (Pubitemid 34863908)
11. Sholook MM, Gilbert JS, Sedeek MH, Huang M, Hester RL, Granger JP. Systemic hemodynamic and regional blood flow changes in response to chronic reductions in uterine perfusion pressure in pregnant rats. Am J Physiol Heart Circ Physiol 2007; 293:H2080-H2084. (Pubitemid 47605844)
12. Gilbert JS, Ryan MJ, LaMarca BB, Sedeek M, Murphy SR, Granger JP. Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction. Am J Physiol Heart Circ Physiol 2008; 294:H541-550. (Pubitemid 351253261)
13. Keiser SD, Veillon EW, Parrish MR, Bennett W, Cockrell K, Fournier L, et al. Effects of 17-hydroxyprogesterone on tumor necrosis factor-alpha-induced hypertension during pregnancy. Am J Hypertens 2009; 22:1120-1125.
14. Walsh SK, English FA, Johns EJ, Kenny LC. Plasma-mediated vascular dysfunction in the reduced uterine perfusion pressure model of preeclampsia: a microvascular characterization. Hypertension 2009; 54:345-351.
15. Li YY, Feng YQ, Kadokami T, McTiernan CF, Draviam R, Watkins SC, Feldman AM. Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by antitumor necrosis factor alpha therapy. Proc Natl Acad Sci USA 2000; 97:12746-12751.
16. Li YY, Kadokami T, Wang P, McTiernan CF, Feldman AM. MMP inhibition modulates TNF-alpha transgenic mouse phenotype early in the development of heart failure. Am J Physiol Heart Circ Physiol 2002; 282:H983-989. (Pubitemid 34654937)
17. LaMarca B, Speed J, Fournier L, Babcock SA, Berry H, Cockrell K, Granger JP. Hypertension in response to chronic reductions in uterine perfusion in pregnant rats: effect of tumor necrosis factor-alpha blockade. Hypertension 2008; 52:1161-1167.
18. Beghetti M, Black SM, Fineman JR. Endothelin-1 in congenital heart disease. Pediatr Res 2005; 57:16R-20R. (Pubitemid 40593241)
19. Jankowski M. GATA4, a new regulator of cardiac fibroblasts, is sensitive to natriuretic peptides. Cardiovasc Res 2009; 84:176-177.
20. Gutkowska J, Paquette A, Wang D, Lavoie JM, Jankowski M. Effect of exercise training on cardiac oxytocin and natriuretic peptide systems in ovariectomized rats. Am J Physiol Regul Integr Comp Physiol 2007; 293:R267-275. (Pubitemid 47092184)
21. Jankowski M, Wang D, Danalache B, Gangal M, Gutkowska J. Cardiac oxytocin receptor blockade stimulates adverse cardiac remodeling in ovariectomized spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 2010; 299:H265-274.
22. Novelli GP, Valensise H, Vasapollo B, Larciprete G, Altomare F, Di Pierro G, et al. Left ventricular concentric geometry as a risk factor in gestational hypertension. Hypertension 2003; 41:469-475. (Pubitemid 36314618)
23. LaMarca BB, Bennett WA, Alexander BT, Cockrell K, Granger JP. Hypertension produced by reductions in uterine perfusion in the pregnant rat: role of tumor necrosis factor-alpha. Hypertension 2005; 46:1022-1025.
24. LaMarca BD, Ryan MJ, Gilbert JS, Murphy SR, Granger JP. Inflammatory cytokines in the pathophysiology of hypertension during preeclampsia. Curr Hypertens Rep 2007; 9:480-485.
25. Lefer AM, Ma XL. Cytokines and growth factors in endothelial dysfunction. Crit Care Med 1993; 21:S9-14.
26. Wang P, Ba ZF, Chaudry IH. Administration of tumor necrosis factor-alpha in vivo depresses endothelium-dependent relaxation. Am J Physiol 1994; 266:H2535-2541.
27. Dorge H, Schulz R, Belosjorow S, Post H, van de Sand A, Konietzka I. Coronary microembolization: the role of TNF-alpha in contractile dysfunction. J Mol Cell Cardiol 2002; 34:51-62. (Pubitemid 34146395)
28. Schulz R, Aker S, Belosjorow S, Heusch G. TNFalpha in ischemia/ reperfusion injury and heart failure. Basic Res Cardiol 2004; 99:8-11. (Pubitemid 38049134)
29. Jankowski M, Bissonauth V, Gao L, Gangal M, Wang D, Danalache B, et al. Anti-inflammatory effect of oxytocin in rat myocardial infarction. Basic Res Cardiol 2010; 105:205-218.
30. Ebermann L, Piper C, Kuhl U, Klingel K, Schlattner U, Siafarikas N, et al. Impact of myocardial inflammation on cytosolic and mitochondrial creatine kinase activity and expression. Basic Res Cardiol 2010; 104:247-257.
31. Giardina JB, Green GM, Cockrell KL, Granger JP, Khalil RA. TNF-alpha enhances contraction and inhibits endothelial NO-cGMP relaxation in systemic vessels of pregnant rats. Am J Physiol Regul Integr Comp Physiol 2002; 283:R130-143. (Pubitemid 34863918)
32. Madhusudan S, Muthuramalingam SR, Braybrooke JP, Wilner S, Kaur K, Han C, et al. Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer. J Clin Oncol 2005; 23:5950-5959.
33. Korth-Bradley JM, Rubin AS, Hanna RK, Simcoe DK, Lebsack ME. The pharmacokinetics of etanercept in healthy volunteers. Ann Pharmacother 2000; 34:161-164. (Pubitemid 30082972)
34. Jobe LJ, Melendez GC, Levick SP, Du Y, Brower GL, Janicki JS. TNF-alpha inhibition attenuates adverse myocardial remodeling in a rat model of volume overload. Am J Physiol Heart Circ Physiol 2009; 297:H1462- 1468.
35. Falcao S, Stoyanova E, Cloutier G, Maurice RL, Gutkowska J, Lavoie J. Mice overexpressing both human angiotensinogen and human renin as a model of superimposed preeclampsia on chronic hypertension. Hypertension 2009; 54:1401-1407.
36. Lubien E, DeMaria A, Krishnaswamy P, Clopton P, Koon J, Kazanegra R, et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation 2002; 105:595-601. (Pubitemid 34123434)
37. McDonagh TA, Robb SD, Murdoch DR, Morton JJ, Ford I, Morrison CE, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998; 351:9-13. (Pubitemid 28020159)
38. Buitrago M, Lorenz K, MaassAH, Oberdorf-Maass S, Keller U, Schmitteckert EM, et al. The transcriptional repressor Nab1 is a specific regulator of pathological cardiac hypertrophy. Nat Med 2005; 11:837-844. (Pubitemid 41161115)
39. Miyata S, Minobe W, Bristow MR, Leinwand LA. Myosin heavy chain isoform expression in the failing and nonfailing human heart. Circ Res 2000; 86:386-390. (Pubitemid 30141756)
40. Robson SC, Hunter S, Boys RJ, Dunlop W. Serial study of factors influencing changes in cardiac output during human pregnancy. Am J Physiol 1989; 256:H1060-H1065.
41. Alonso J, Sanchez de Miguel L, Monton M, Casado S, Lopez-Farre A. Endothelial cytosolic proteins bind to the 30 untranslated region of endothelial nitric oxide synthase mRNA: regulation by tumor necrosis factor alpha. Mol Cell Biol 1997; 17:5719-5726. (Pubitemid 27411079)
42. Sanchez de Miguel L, Alonso J, Gonzalez-Fernandez F, de la Osada J, Monton M, Rodríguez-Feo JA, et al. Evidence that an endothelial cytosolic protein binds to the 30-untranslated region of endothelial nitric oxide synthase mRNA. J Vasc Res 1999; 36:201-208. (Pubitemid 29291196)
43. Yoshizumi M, Perrella MA, Burnett JC Jr, Lee ME. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res 1993; 73:205-209. (Pubitemid 23173071)
44. Jankowski M, Wang D, Hajjar F, Mukaddam-Daher S, McCann SM, Gutkowska J. Oxytocin and its receptors are synthesized in the rat vasculature. Proc Natl Acad Sci USA 2000; 97:6207-6211. (Pubitemid 30367548)
45. Ondrejcakova M, Ravingerova T, Bakos J, Pancza D, Jezova D. Oxytocin exerts protective effects on in vitro myocardial injury induced by ischemia and reperfusion. Can J Physiol Pharmacol 2009; 87:137-142.
46. Kobayashi H, Yasuda S, Bao N, Iwasa M, Kawamura I, Yamada Y, et al. Postinfarct treatment with oxytocin improves cardiac function and remodeling via activating cell-survival signals and angiogenesis. J Cardiovasc Pharmacol 2009; 54:510-519.
47. Cassoni P, Marrocco T, Bussolati B, Allia E, Munaron L, Sapino A, Bussolati G. Oxytocin induces proliferation and migration in immortalized human dermal microvascular endothelial cells and human breast tumor-derived endothelial cells. Mol Cancer Res 2006; 4:351-359. (Pubitemid 44035154)
48. Cattaneo MG, Chini B, Vicentini LM. Oxytocin stimulates migration and invasion in human endothelial cells. Br J Pharmacol 2008; 153:728-736. (Pubitemid 351271756)
49. Cattaneo MG, Lucci G, Vicentini LM. Oxytocin stimulates in vitro angiogenesis via a Pyk-2/Src-dependent mechanism. Exp Cell Res 2009; 315:3210-3219.
50. Buus NH, Bottcher M, Jorgensen CG, Christensen KL, Thygesen K, Mulvany MJ. Myocardial perfusion during long-term angiotensin-converting enzyme inhibition or beta-blockade in patients with essential hypertension. Hypertension 2004; 44:465-470. (Pubitemid 39281497)
51. Greene AS, Tonellato PJ, Lui J, Lombard JH, Cowley AW Jr. Microvascular rarefaction and tissue vascular resistance in hypertension. Am J Physiol 1989; 256:H126-131.
52. Hudlicka O, Brown M, Egginton S. Angiogenesis in skeletal and cardiac muscle. Physiol Rev 1992; 72:369-417.
53. Zhang L, Wheatley CM, Richards SM, Barrett EJ, Clark MG, Rattigan S. TNF-alpha acutely inhibits vascular effects of physiological but not high insulin or contraction. Am J Physiol Endocrinol Metab 2003; 285:E654- 660. (Pubitemid 37010846)